These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 1427960)
1. Liposomal hamycin in the control of experimental aspergillosis in mice: relative toxicity, therapeutic efficacy and tissue distribution of free and liposomal hamycin. Moonis M; Ahmad I; Bachhawat BK Indian J Biochem Biophys; 1992 Aug; 29(4):339-45. PubMed ID: 1427960 [TBL] [Abstract][Full Text] [Related]
2. Mannosylated liposomes as carriers for hamycin in the treatment of experimental aspergillosis in Balb/C mice. Moonis M; Ahmad I; Bachhawat BK J Drug Target; 1993; 1(2):147-55. PubMed ID: 8069553 [TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B. Ahmad I; Sarkar AK; Bachhawat BK Indian J Biochem Biophys; 1989 Dec; 26(6):351-6. PubMed ID: 2698855 [TBL] [Abstract][Full Text] [Related]
4. Liposomal hamycin in the control of experimental aspergillosis in mice: effect of phosphatidic acid with and without cholesterol. Moonis M; Ahmad I; Bachhawat BK J Antimicrob Chemother; 1993 Apr; 31(4):569-79. PubMed ID: 8514651 [TBL] [Abstract][Full Text] [Related]
5. Effect of cholesterol in various liposomal compositions on the in vivo toxicity, therapeutic efficacy, and tissue distribution of amphotericin B. Ahmad I; Sarkar AK; Bachhawat BK Biotechnol Appl Biochem; 1990 Oct; 12(5):550-6. PubMed ID: 2288711 [TBL] [Abstract][Full Text] [Related]
6. Liposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo. Mehta RT; McQueen TJ; Keyhani A; Lopez-Berestein G J Infect Dis; 1991 Nov; 164(5):1003-6. PubMed ID: 1940451 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic activity of liposomal SJA-95: a new polyene macrolide antibiotic in experimental aspergillosis and cryptococcosis. Desai SK; Naik SR Biomed Pharmacother; 2009 May; 63(4):287-92. PubMed ID: 18848764 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins. Chakraborty KK; Naik SR J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435 [TBL] [Abstract][Full Text] [Related]
9. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. Khan MA; Owais M J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592 [TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. Bellocchio S; Gaziano R; Bozza S; Rossi G; Montagnoli C; Perruccio K; Calvitti M; Pitzurra L; Romani L J Antimicrob Chemother; 2005 Feb; 55(2):214-22. PubMed ID: 15649994 [TBL] [Abstract][Full Text] [Related]
11. Hamycin therapy of murine disseminated candidiasis: efficacy and interaction with fluconazole. Dhuley JN Rocz Akad Med Bialymst; 2001; 46():326-33. PubMed ID: 11780576 [TBL] [Abstract][Full Text] [Related]
12. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374 [TBL] [Abstract][Full Text] [Related]
14. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis. Le Conte P; Joly V; Saint-Julien L; Gillardin JM; Carbon C; Yeni P Am Rev Respir Dis; 1992 Feb; 145(2 Pt 1):424-9. PubMed ID: 1310577 [TBL] [Abstract][Full Text] [Related]
15. Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation. BitMansour A; Brown JM J Infect Dis; 2002 Jul; 186(1):134-7. PubMed ID: 12089676 [TBL] [Abstract][Full Text] [Related]
16. Liposomal amphotericin-B as a therapeutic measure to control experimental aspergillosis in BALB/c mice. Ahmad I; Sarkar AK; Bachhawat BK Indian J Biochem Biophys; 1990 Dec; 27(6):370-4. PubMed ID: 2102483 [No Abstract] [Full Text] [Related]
17. Mannose-coated liposomal hamycin in the treatment of experimental leishmaniasis in hamsters. Banerjee G; Bhaduri AN; Basu MK Biochem Med Metab Biol; 1994 Oct; 53(1):1-7. PubMed ID: 7857676 [TBL] [Abstract][Full Text] [Related]
18. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Yuan ZP; Chen LJ; Fan LY; Tang MH; Yang GL; Yang HS; Du XB; Wang GQ; Yao WX; Zhao QM; Ye B; Wang R; Diao P; Zhang W; Wu HB; Zhao X; Wei YQ Clin Cancer Res; 2006 May; 12(10):3193-9. PubMed ID: 16707620 [TBL] [Abstract][Full Text] [Related]
19. Tuftsin-mediated immunoprophylaxis against an isolate of Aspergillus fumigatus shows less in vivo susceptibility to amphotericin B. Khan MA; Ahmad N; Moin S; Mannan A; Wajahul H; Pasha ST; Khan A; Owais M FEMS Immunol Med Microbiol; 2005 Jun; 44(3):269-76. PubMed ID: 15907448 [TBL] [Abstract][Full Text] [Related]
20. Aerosol hamycin is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Dhuley JN Rocz Akad Med Bialymst; 2001; 46():317-25. PubMed ID: 11780575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]